Calcium antagonists show no increased mortality after adjustments for patient differences in Israeli study.
CALCIUM ANTAGONISTS DO NOT SHOW INCREASED MORTALITY AFTER ADJUSTMENTS for differences between patients receiving calcium channel blockers and those not taking the drugs in an Israeli observational study published in the July issue of the Journal of the American College of Cardiology. "The current analysis does not support the claim that calcium antagonist therapy in patients with coronary artery disease, whether myocardial infarction survivors or others, harbors an increased risk of mortality," state the authors Shimon Braun, MD, et al., Tel Aviv Medical Center.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth